Big pharmaceutical and insurance companies have played a central role in the pandemic, racing to find a scientific solution to the nightmare virus and covering associated costs, like Covid-19 testing. But the pandemic has also been good for many healthcare businesses.
Johnson & Johnson, which has developed a single-shot Covid-19 vaccine, is the largest public healthcare company in the world as of mid-April. Johnson & Johnson, the pharmaceutical and consumer goods giant, developed the third vaccine authorized for use in the U.S. It ranks No. 1 among healthcare companies and No. 34 overall on the. The company’s stock has climbed steadily over the last six months, despite a 10-day pause in its U.S.
The financial impact of producing a Covid-19 vaccine has at times been complicated. Pfizer, which developed the first Covid-19 vaccine authorized in the U.S. in partnership with German company BioNTech, lands at No. 3 on the list. In anreleased in May, Pfizer said that its vaccine brought in $3.5 billion in global revenue in the first three months of the year. But that has not helped Pfizer’s stock, which is trading at the same level as it did two years ago.